London, United Kingdom – At the CARTCR Summit in London, Senior Scientist Venera Kuci Emruli from Strike Pharma presented the company’s work on non-viral in-vivo CAR-T engineering, highlighting the potential for scalable manufacturing, simplified production processes, and future clinical translation.

The presentation generated valuable discussions around the next generation of in-vivo cell therapy approaches and provided an opportunity to engage with researchers, clinicians, and industry leaders working at the forefront of the field.

About Strike Pharma (www.strikepharma.com)

Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as cancer immunotherapeutic treatments. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.

Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.

Enquiries

Mårten Winge CEO

+46 (0) 70 657 59 27

[email protected]